What Zimmer Biomet’s Progress II Study Success Could Mean




On December 22, 2017, Zimmer Biomet Holdings (ZBH) published the results of its Progress II trial, and the results were positive. The trial demonstrated the safety and efficacy of ZBH’s nSTRIDE APS (autologous protein solution) kit, which is used to treat knee OA (osteoarthritis).

OA is a common type of arthritis and progressive joint disease that occurs when the top layer of cartilage wears away after breaking down. When this layer wears away, the bones under the cartilage lose motion at the joint and swell as the bones rub together.

On December 22, 2017, ZBH stock gained ~0.14%. On the same day, the iShares Russell Mid-Cap Value ETF (IWS) rose by approximately 0.20%. IWS has ~0.61% of its total holdings in ZBH.

Article continues below advertisement

Brief details of the Progress II trial

The Progress II trial was a randomized, prospective, saline-controlled, double-blind pilot study that included 46 patients suffering from symptomatic knee OA. The trial was conducted at four sites across Europe and consisted of investigators using ZBH’s nSTRIDE APS kit.

Trial results

The results of the trial were published in The American Journal of Sports Medicine. The results showed “significant improvement in the percentage change from baseline in pain scores measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), as well as comparable safety to saline.”

Notably, other companies in the US medical device industry working toward the treatment of OA include Stryker (SYK), Smith and Nephew (SNN), and Medtronic (MDT).


More From Market Realist